<DOC>
	<DOCNO>NCT00004263</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . UCN-01 may make cancer cell sensitive cytarabine . PURPOSE : Phase I trial study effectiveness cytarabine UCN-01 treating patient refractory relapse acute myelogenous leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Cytarabine UCN-01 Treating Patients With Refractory Relapsed Acute Myelogenous Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose cytarabine combine UCN-01 patient refractory relapse acute myelogenous leukemia myelodysplastic syndrome . II . Determine dose limit toxicity , pharmacokinetics , pharmacodynamics regimen patient . III . Assess antileukemia effect regimen patient population . OUTLINE : This dose escalation , multicenter study cytarabine . Patients receive cytarabine IV 24 hour day 1-4 course . Patients receive UCN-01 IV 24 hour day 2-4 course 1 36 hour begin day 2 subsequent course . Treatment repeat every 4 week maximum 4 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos cytarabine maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : A maximum 30 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>1 . 1 . Patients refractory relapse acute myelogenous leukemia , myelodysplastic syndrome ( RAEB RAEBT ) . 2 . 2 . Performance status = &lt; 2 3 . 3 . Signed informed consent indicate patient aware investigational nature study keep policy hospital . The acceptable consent form one attached end protocol participate institution . 4 . 4 . Patients must chemotherapy 2 week prior enter study recover toxic effect therapy , unless evidence rapidly progressive disease . 5 . 5 . Bilirubin creatinine ( creatinine clearance ) within institutional normal limit . 6 . 6 . Patients must relapse fail respond highdose araCbased ( &gt; =1g/m2/day x 3 day ) chemotherapy . 7 . 7 . Corrected DLCO &gt; 50 % . 8 . 8 . Patients &gt; =3 cardiac risk factor ( smoking , hypertension , family history coronary artery disease , diabetes mellitus , hypercholesterolemia ) nuclear medicine stress test . 1 . 1 . The antiproliferative activity experimental drug may harmful develop fetus nursing infant . Therefore , pregnant nursing female exclude . Patients childbearing potential practice effective method contraception . 2 . 2 . Patients eligible allogeneic marrow transplant donor offer transplant . 3 . 3 . Patients exist pulmonary disease , history coronary artery disease receive radiotherapy mediastinum .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>cytarabine</keyword>
	<keyword>7-hydroxystaurosporine</keyword>
	<keyword>UCN-01</keyword>
</DOC>